| Literature DB >> 34985368 |
Samaneh Soleymani1, Ayeh Naghizadeh2, Mehrdad Karimi2, Azadeh Zarei2, Raefeh Mardi1, Gholamreza Kordafshari1, Niusha Esmaealzadeh1, Arman Zargaran1.
Abstract
The coronavirus disease-2019 (COVID-19) pandemic started in early 2020 with the outbreak of a highly pathogenic human coronavirus. The world is facing a challenge and there is a pressing need for efficient drugs. Plants and natural compounds are a proven rich resource for new drug discovery. Considering the potential of natural products to manage the pandemic, this article was designed to provide an inclusive map of the stages and pathogenetic mechanisms for effective natural products on COVID-19. New drug discovery for the COVID-19 pandemic can encompass both prevention and disease management strategies. Preventive mechanisms that may be considered include boosting the immune response and hand hygiene in the preexposure phase; and blocking of virus binding and entry in the postexposure phase. Potential therapeutic target mechanisms include virus-directed therapies and host-directed therapies. Several medicinal plants and natural products, such as Withania somnifera (L.) Dunal and propolis for prevention; Tanacetum parthenium (L.) for treatment; and Ammoides verticillata (Desf.) Briq and Nigella sativa L. for both prevention and treatment have been found effective and are good targets for future research. The examples of phytochemical compounds that may be effective include aloin and terpenes as anti-septics; isothymol, dithymoquinone, and glycyrrhizin as inhibitors of virus binding and entry; glycyrrhizin, and berberine as replication suppressants; ginsenoside Rg1 and parthenolide as immunomodulators; and eriocitrin, rhoifolin, hesperidin, naringin, rutin, and veronicastroside as anti-complements. Recognizing different mechanisms of fighting against this virus can lead to a more systematic approach in finding natural products and medicinal plants for COVID-19 prevention and treatment.Entities:
Keywords: COVID-19; angiotensin-converting enzyme; coronavirus; new drug discovery; phytotherapy; plant extracts
Mesh:
Year: 2022 PMID: 34985368 PMCID: PMC8744081 DOI: 10.1177/2515690X211053641
Source DB: PubMed Journal: J Evid Based Integr Med ISSN: 2515-690X
Figure 1.Strategies for prevention and treatment of coronavirus disease 2019 (COVID-19) by medicinal herbs.
Target Mechanisms of Drug Discovery From Natural Resources for COVID-19 With Example Studies.
| Source | Phytochemical | Structure of Phytochemicals | Study design | Mechanism | Ref | |
|---|---|---|---|---|---|---|
|
| Aloin and aloe- emodin |
|
| Inhibiting the viral replication or destructing the virus lipid envelope | 26 | |
| Terpenes |
|
| Disrupting the viral membrane fusion procedure and viral replication | 25 | ||
|
| Animal (Rat) | Boosting immune system cells and suppressing production of proinflammatory cytokines | 20, 22 | |||
|
| Isothymol |
| In silico | ACE inhibitors | 30 | |
| Dithymoquinone (DTQ) |
| In silico | ACE2 inhibitor | 33 | ||
| Glycyrrhizin |
| In silico | ACE2 inhibitor | 85 | ||
| Propolis | Myricetin, Caffeic acid phenethyl ester, Hesperetin, Pinocembrin |
| In silico | Inhibitory potential with high binding energy to ACE2 (-8.97 kcal/mol) | 86 | |
| Kaempferol |
| In silico | Inhibitory potential with high binding energy to ACE2 (-7.5 kcal/mol) | 87 | ||
| Quercetin |
| In silico | Inhibitory potential with high binding energy to ACE2 (-10.4 kcal/mol) | 88 | ||
| Withaferin-A, Withanone, Caffeic acid phenethyl ester |
| In silico, | TPMRSS2 inhibition | 28 | ||
| Rugosanine B |
| Computational screening | Cathepsin L inhibition | 2 | ||
| Ararobinol |
| Computational screening | Cathepsin L inhibition | 2 | ||
| (+)- oxoturkiyenine |
| Computational screening | Cathepsin L inhibition | 2 | ||
| 3α,17α-cinchophylline |
| Computational screening | Cathepsin L inhibition | 2 | ||
| Trichotomine |
| Computational screening | Cathepsin L inhibition | 2 | ||
| Tectol |
| Computational screening | Cathepsin L inhibition | 2 | ||
| Silymonin |
| Computational screening | Cathepsin L inhibition | 2 | ||
| Picrasidine M |
| Computational screening | Cathepsin L inhibition | 2 | ||
| Juglone |
| Computational screening | Cathepsin L inhibition | 2 | ||
|
| Berberine |
| In silico | Inhibition of 3CLpro function | 45 | |
|
| Inhibition of TRP gene expression | 57 | ||||
| In silico | Inhibition of N protein | 48 | ||||
| Glycyrrhizin |
|
| Inhibition of viral replication | 56 | ||
|
|
| Enhancement of CD4+/CD8+ T cell ratio, inhibition of IL-Ιβ, TNF- α, and IFN-γ expression | 74 | |||
| Ginsenoside Rg1 |
| Enhancement of CD4+ T cell activity | 72 | |||
| Parthenolide |
|
| Inhibition of IL-1, IL-2, IL-6, IL-8, and TNF-α expression | 79 | ||
| Sch.Bip. (feverfew) | ||||||
|
| Enhancement of CD4+ T cell migration | 75 | ||||
|
| Inhibition of IL-1beta, IL- 2, IL-6, IL-12 and TNF-α expression | 76 | ||||
| Propolis | Caffeic acid, and Caffeic acid phenethyl ester |
| Downregulation and inhibition of PAK1 | 35 | ||
|
| Anticomplement and antiinflammatory effects | 89 | ||||
|
| Eriocitrin/ neoeriocitrin, rhoifolin, hesperidin, naringin, rutin, veronicastroside, neohesperidin, and hesperetin |
|
| Anticomplement and antiinflammatory effects | 81 | |
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
|